Celldex Therapeutics Inc (CLDX) Stock AnalysisCLDXCelldex Therapeutics Inc

Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Celldex Therapeutics Inc is currently not a strong buy due to its low RSI of 27.687, indicating oversold conditions, and a significant 28.01% decline over the last 20 days. However, the positive news regarding the efficacy of Barzolvolimab and raised price targets from analysts suggest potential upside. The main risk is the ongoing investigation into the company's directors, which could impact shareholder confidence.

7 analysts cover CLDX: 4 rate it Buy, 3 Hold and 0 Sell. The average price target is 55.00.